Molly Klote, Klote Medical Research Advisors, discusses how pharma must move beyond tariff-driven reactions to build evidence-based, quality-led supply chain resilience that satisfies FDA scrutiny and protects patient access.
Molly Klote
Advertisement
President and CEO, Klote Medical Research Advisors
Articles by Molly Klote
At CPHI Americas, Molly Klote, Klote Medical Research Advisors, spoke about how the pharma industry faces tariff volatility and reshoring pressure. She warned FDA wants actionable supply chain plans, not slogans, with quality built in.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pharma Fundamentals: Hold Times in Biopharmaceuticals
2
IPEC’s Excipient Information Package: A Standardized Communication Platform for Sharing Excipient Information as an Alternative to Questionnaires
3
FDA Updates Master Protocol: What Developers Need to Know
4
Merck KGaA Launches Saturnus Bio; Announces Awards
5